200 related articles for article (PubMed ID: 28994710)
1. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.
Kutzsche J; Schemmert S; Tusche M; Neddens J; Rabl R; Jürgens D; Brener O; Willuweit A; Hutter-Paier B; Willbold D
Molecules; 2017 Oct; 22(10):. PubMed ID: 28994710
[TBL] [Abstract][Full Text] [Related]
2. Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species.
Ziehm T; Brener O; van Groen T; Kadish I; Frenzel D; Tusche M; Kutzsche J; Reiß K; Gremer L; Nagel-Steger L; Willbold D
ACS Chem Neurosci; 2016 Aug; 7(8):1088-96. PubMed ID: 27240424
[TBL] [Abstract][Full Text] [Related]
3. Optimization of d-Peptides for Aβ Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic Aβ Oligomers.
Klein AN; Ziehm T; van Groen T; Kadish I; Elfgen A; Tusche M; Thomaier M; Reiss K; Brener O; Gremer L; Kutzsche J; Willbold D
ACS Chem Neurosci; 2017 Sep; 8(9):1889-1900. PubMed ID: 28581708
[TBL] [Abstract][Full Text] [Related]
4. Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2.
Schemmert S; Schartmann E; Honold D; Zafiu C; Ziehm T; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Neurobiol Dis; 2019 Apr; 124():36-45. PubMed ID: 30391539
[TBL] [Abstract][Full Text] [Related]
5. Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology.
Schemmert S; Schartmann E; Zafiu C; Kass B; Hartwig S; Lehr S; Bannach O; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Mol Neurobiol; 2019 Mar; 56(3):2211-2223. PubMed ID: 30003517
[TBL] [Abstract][Full Text] [Related]
6. SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease.
Brunner D; Flunkert S; Neddens J; Duller S; Scopes DIC; Treherne JM; Hutter-Paier B
Neurosci Lett; 2017 Nov; 660():96-102. PubMed ID: 28917978
[TBL] [Abstract][Full Text] [Related]
7. Aβ oligomer eliminating compounds interfere successfully with pEAβ(3-42) induced motor neurodegenerative phenotype in transgenic mice.
Dunkelmann T; Teichmann K; Ziehm T; Schemmert S; Frenzel D; Tusche M; Dammers C; Jürgens D; Langen KJ; Demuth HU; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Neuropeptides; 2018 Feb; 67():27-35. PubMed ID: 29273382
[TBL] [Abstract][Full Text] [Related]
8. The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.
van Groen T; Schemmert S; Brener O; Gremer L; Ziehm T; Tusche M; Nagel-Steger L; Kadish I; Schartmann E; Elfgen A; Jürgens D; Willuweit A; Kutzsche J; Willbold D
Sci Rep; 2017 Nov; 7(1):16275. PubMed ID: 29176708
[TBL] [Abstract][Full Text] [Related]
9. Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.
Aileen Funke S; van Groen T; Kadish I; Bartnik D; Nagel-Steger L; Brener O; Sehl T; Batra-Safferling R; Moriscot C; Schoehn G; Horn AH; Müller-Schiffmann A; Korth C; Sticht H; Willbold D
ACS Chem Neurosci; 2010 Sep; 1(9):639-48. PubMed ID: 22778851
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease.
Wu X; Kosaraju J; Zhou W; Tam KY
ACS Chem Neurosci; 2017 Mar; 8(3):676-685. PubMed ID: 28032988
[TBL] [Abstract][Full Text] [Related]
11. Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged AβPP/PS1 double transgenic mice.
van Groen T; Kadish I; Funke SA; Bartnik D; Willbold D
J Alzheimers Dis; 2013; 34(3):609-20. PubMed ID: 23271316
[TBL] [Abstract][Full Text] [Related]
12. Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization.
Teng E; Taylor K; Bilousova T; Weiland D; Pham T; Zuo X; Yang F; Chen PP; Glabe CG; Takacs A; Hoffman DR; Frautschy SA; Cole GM
Neurobiol Dis; 2015 Oct; 82():552-560. PubMed ID: 26369878
[TBL] [Abstract][Full Text] [Related]
13. Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.
Ribeiro CA; Oliveira SM; Guido LF; Magalhães A; Valencia G; Arsequell G; Saraiva MJ; Cardoso I
J Alzheimers Dis; 2014; 39(2):357-70. PubMed ID: 24169237
[TBL] [Abstract][Full Text] [Related]
14. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL
Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884
[TBL] [Abstract][Full Text] [Related]
15. Probing amyloid-β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry.
Carlred L; Michno W; Kaya I; Sjövall P; Syvänen S; Hanrieder J
J Neurochem; 2016 Aug; 138(3):469-78. PubMed ID: 27115712
[TBL] [Abstract][Full Text] [Related]
16. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
[TBL] [Abstract][Full Text] [Related]
17. QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.
Brener O; Dunkelmann T; Gremer L; van Groen T; Mirecka EA; Kadish I; Willuweit A; Kutzsche J; Jürgens D; Rudolph S; Tusche M; Bongen P; Pietruszka J; Oesterhelt F; Langen KJ; Demuth HU; Janssen A; Hoyer W; Funke SA; Nagel-Steger L; Willbold D
Sci Rep; 2015 Sep; 5():13222. PubMed ID: 26394756
[TBL] [Abstract][Full Text] [Related]
18. Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration.
Liu P; Reed MN; Kotilinek LA; Grant MK; Forster CL; Qiang W; Shapiro SL; Reichl JH; Chiang AC; Jankowsky JL; Wilmot CM; Cleary JP; Zahs KR; Ashe KH
Cell Rep; 2015 Jun; 11(11):1760-71. PubMed ID: 26051935
[TBL] [Abstract][Full Text] [Related]
19. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.
Brody DL; Jiang H; Wildburger N; Esparza TJ
Alzheimers Res Ther; 2017 Aug; 9(1):62. PubMed ID: 28818091
[TBL] [Abstract][Full Text] [Related]
20. EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques.
Kim HY; Kim HV; Jo S; Lee CJ; Choi SY; Kim DJ; Kim Y
Nat Commun; 2015 Dec; 6():8997. PubMed ID: 26646366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
